On September 30, 2021 Infant Bacterial Therapeutics (IBT) announced that the company had reached a key milestone in the development of IBP-9414, after...
Infant Bacterial Therapeutics AB (IBT) today announces that the Australian Patent Office has granted a patent entitled: A method of activating lactic acid...
Infant Bacterial Therapeutics AB today announces that the Patent Offices of Brazil and Hong Kong have approved a patent of Lactobacillus reuteri covering...
Infant Bacterial Therapeutics ABs CFO Marie Louise Alamaa left the company to pursue new opportunities. IBT’s Controller, Michael Owens, has assumed...
A blinded evaluation of IBT’s Connection Study will be presented by Professor Josef Neu, University of Florida, at the 2021 Hot Topics in Neonatology®...
Stockholm, October 29, 2021. The Chairman of IBT has established a Nomination Committee for the AGM, which is planned to be held on May 4, 2022. The Nomination...
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021 Message from the CEO As is well known, IBT is conducting a large phase...
Infant Bacterial Therapeutics (IBT) announces that the company has reached the next important milestone after recruiting 600 premature infants in the ongoing...
After safety review The Connection study is now again open to recruit the smallest infants. Following the completion of the DMC (Data Monitoring Committee)...
Infant Bacterial Therapeutics today announces that a new patent is granted in Mexico Infant Bacterial Therapeutics AB today announces that the Mexican...